Skip to content
value.today

Structure Therapeutics Inc.

GPCR
$4.7 Bmarket cap on Oct 20, 2026
Compare
World rank
#3,728
Revenue
—
For year ending December-2025
Net income
$-141 M
SEC filing
Employees
220
As of December 31, 2025
SEC filing

Structure Therapeutics Inc. in brief

Structure Therapeutics Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $4.7 B on 20 October 2026, which makes it the 3,728th largest listed company in the world and the 1,087th largest in the USA on this site. It employs about 220 people. Its shares trade under the symbol GPCR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Structure Therapeutics Inc.

We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors. These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for the treatment of various metabolic, cardiovascular and pulmonary disorders. By leveraging our world-class GPCR know-how, we are designing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies that target this family of receptors.

From the company's annual report filed with the US SEC: read the report

Structure Therapeutics Inc. timeline

3 events, 2021–2023
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2022
  4. ✎
    Renamed Structure Therapeutics Inc.
    Formerly ShouTi Inc..
  5. 2023
  6. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 6 February 2023; shares registered for exchange trading on 30 January 2023.

Events of Structure Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1.3 B$2.6 B$3.9 B$5.2 B

World rank over time

▼ down 20 places since 2026
2026-10-14: #3714#3,71420262026-10-20: #3734#3,7342026

Rank in USA: #1,081 (Oct 2026) · #1,088 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.1×
Free cash flow yield
-4.8%
Net margin
—
Operating margin
—
Return on equity
-9.3%
Liabilities / assets
4.3%
Profit per employee
$-642 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2022: revenue —, net income $-51M—FY22Fiscal year ending Dec 2023: revenue —, net income $-90M—FY23Fiscal year ending Dec 2024: revenue —, net income $-123M—FY24Fiscal year ending Dec 2025: revenue —, net income $-141M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-177M$-141M—
Dec 2024——$-158M$-123M—
Dec 2023——$-103M$-90M—
Dec 2022——$-53M$-51M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-222M$4M$-226M$-0.80—
Dec 2024$-117M$1M$-118M$-0.78—
Dec 2023$-79M$2M$-82M$-0.81—
Dec 2022$-46M$0M$-46M$-5.51—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-36M—Dec ’24Three months to Mar 2025: revenue —, net income $-47M—Mar ’25Three months to Jun 2025: revenue —, net income $-62M—Jun ’25Three months to Sep 2025: revenue —, net income $-66M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $33M—Dec ’25Three months to Mar 2026: revenue —, net income $-76M—Mar ’26Three months to Jun 2026: revenue —, net income $-106M—Jun ’26Three months to Sep 2026: revenue —, net income $-145M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-145M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Structure Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-177 M
Net income
$-141 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$1.6 B
Total liabilities
$68 M
Total equity
$1.5 B

As of December-2025

Top 100 institutional investors in Structure Therapeutics Inc.#

As of Sep 30, 2026
171 institutions held 68.0 M shares (about 31.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 21.6%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Structure Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Wellington Management Group LLP9,762,981+2,383,548 (+32.30%)4.55%$305 MNov 16, 2026
2FMR LLC9,354,478+1,544,172 (+19.77%)4.36%$293 MNov 10, 2026
3Avoro Capital Advisors LLC6,555,5550 (0.00%)3.05%$205 MNov 16, 2026
4Janus Henderson Group Ltd.5,070,156—2.36%$159 MNov 16, 2026
5Deep Track Capital, LP5,000,000+259,928 (+5.48%)2.33%$156 MNov 16, 2026
6Morgan Stanley2,816,776+10,136 (+0.36%)1.31%$88 MNov 13, 2026
7BVF Inc/il2,691,426-675,397 (-20.06%)1.25%$84 MNov 16, 2026
8RTW Investments, LP2,282,138+674,631 (+41.97%)1.06%$71 MNov 16, 2026
9Baker Bros. Advisors LP1,432,5290 (0.00%)0.67%$45 MNov 16, 2026
10Orbimed Advisors LLC1,331,000-878,400 (-39.76%)0.62%$42 MNov 16, 2026
11Paradigm Biocapital Advisors LP1,299,199New0.60%$41 MNov 16, 2026
12Principal Financial Group Inc1,264,946-487,807 (-27.83%)0.59%$40 MNov 2, 2026
13Deerfield Management Company, L.P.1,086,0000 (0.00%)0.51%$34 MNov 16, 2026
14Casdin Capital, LLC1,030,000-145,000 (-12.34%)0.48%$32 MNov 16, 2026
15Logos Global Management LP1,000,000+500,000 (+100.00%)0.47%$31 MNov 16, 2026
16Siren, L.L.C.872,9670 (0.00%)0.41%$27 MNov 12, 2026
17Aberdeen Group plc858,784+218,869 (+34.20%)0.40%$27 MNov 10, 2026
18Capitolis Liquid Global Markets LLC835,000-206,100 (-19.80%)0.39%$26 MNov 12, 2026
19Driehaus Capital Management LLC803,818-749,401 (-48.25%)0.37%$25 MNov 16, 2026
20Pacific Heights Asset Management LLC800,0000 (0.00%)0.37%$25 MNov 3, 2026
21BlackRock, Inc.705,946+194,797 (+38.11%)0.33%$22 MNov 13, 2026
22Rock Springs Capital Management LP640,3170 (0.00%)0.30%$20 MNov 16, 2026
23Alliancebernstein L.P.581,971-29,737 (-4.86%)0.27%$18 MNov 16, 2026
24Jpmorgan Chase & Co546,189+542,205 (+13609.56%)0.25%$17 MNov 12, 2026
25Blue Sparrow, LLC /DE473,200New0.22%$15 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Structure Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Two Sigma Investments, LP442,107+237,951 (+116.55%)0.21%$14 MNov 16, 2026
27Goldman Sachs Group Inc431,311+188,521 (+77.65%)0.20%$13 MNov 16, 2026
28Price T Rowe Associates Inc /MD/378,228-467,304 (-55.27%)0.18%$12 MNov 16, 2026
29Franklin Templeton Inc371,271-207,568 (-35.86%)0.17%$12 MNov 12, 2026
30UBS Group AG332,122-46,864 (-12.37%)0.15%$10 MNov 10, 2026
31National Bank Of Canada /fi/318,545+102,745 (+47.61%)0.15%$10 MNov 16, 2026
32NEXTBio Capital Management LP312,4960 (0.00%)0.15%$10 MNov 13, 2026
33American Century Companies Inc303,882-1,378,297 (-81.94%)0.14%$10 MNov 12, 2026
34Parkman Healthcare Partners LLC283,763-201,898 (-41.57%)0.13%$9 MNov 16, 2026
35HSG Holding Ltd266,0620 (0.00%)0.12%$8 MNov 13, 2026
36Catalio Capital Management, LP260,109-16,441 (-5.95%)0.12%$8 MNov 16, 2026
37SEB Asset Management AB245,0430 (0.00%)0.11%$8 MNov 4, 2026
38Jane Street Group, LLC232,677New0.11%$7 MNov 12, 2026
39Trexquant Investment LP200,230New0.09%$6 MNov 16, 2026
40Rhenman & Partners Asset Management AB183,300+38,200 (+26.33%)0.09%$6 MNov 12, 2026
41B Group, Inc.180,000+40,000 (+28.57%)0.08%$6 MNov 16, 2026
42HighVista Strategies LLC170,193+39,409 (+30.13%)0.08%$5 MNov 13, 2026
43Eversept Partners, LP155,127-41,175 (-20.98%)0.07%$5 MNov 16, 2026
44Woodline Partners LP153,886+78 (+0.05%)0.07%$5 MNov 16, 2026
45Bank Of America Corp /de/149,978-413,444 (-73.38%)0.07%$5 MNov 16, 2026
46Universal- Beteiligungs- und Servicegesellschaft mbH140,623+14,934 (+11.88%)0.07%$4 MNov 10, 2026
47Susquehanna International Group, LLP136,435+14,091 (+11.52%)0.06%$4 MNov 16, 2026
48Healthcare Of Ontario Pension Plan Trust Fund135,299-283,501 (-67.69%)0.06%$4 MNov 13, 2026
49Jefferies Financial Group Inc.122,322+81,697 (+201.10%)0.06%$4 MNov 5, 2026
50Walleye Capital LLC118,391New0.06%$4 MNov 13, 2026
51Citadel Advisors LLC116,295New0.05%$4 MNov 16, 2026
52D. E. Shaw & Co., Inc.115,3000 (0.00%)0.05%$4 MNov 16, 2026
53Peregrine Capital Management LLC114,982+22,753 (+24.67%)0.05%$4 MNov 9, 2026
54Susquehanna Portfolio Strategies, LLC113,904-35,044 (-23.53%)0.05%$4 MNov 16, 2026
55Marshall Wace, LLP108,366-159,226 (-59.50%)0.05%$3 MNov 13, 2026
56Geode Capital Management, LLC105,636+8,453 (+8.70%)0.05%$3 MNov 6, 2026
57Squarepoint Ops LLC104,907-20,668 (-16.46%)0.05%$3 MNov 9, 2026
58Nomura Asset Management International Inc.96,968-56,151 (-36.67%)0.05%$3 MNov 16, 2026
59Alps Advisors Inc94,499+22,666 (+31.55%)0.04%$3 MNov 3, 2026
60State Street Corp92,556+47,927 (+107.39%)0.04%$3 MNov 12, 2026
61Platinum Investment Management LTD90,3630 (0.00%)0.04%$3 MNov 16, 2026
62Qube Research & Technologies Ltd85,415-7,988 (-8.55%)0.04%$3 MNov 13, 2026
63Millennium Management LLC80,675-8,893 (-9.93%)0.04%$3 MNov 16, 2026
64PFM Health Sciences, LP66,404-25,146 (-27.47%)0.03%$2 MNov 16, 2026
65HRT Financial LP65,055New0.03%$2 MNov 13, 2026
66Voloridge Investment Management, LLC60,300-52,000 (-46.30%)0.03%$2 MNov 16, 2026
67Burkehill Global Management, LP60,0000 (0.00%)0.03%$2 MNov 16, 2026
68Buckland Partners Management Co LLC60,000+10,000 (+20.00%)0.03%$2 MNov 13, 2026
69XTX Topco Ltd55,586New0.03%$2 MNov 16, 2026
70Brevan Howard Capital Management LP51,516-8,820 (-14.62%)0.02%$2 MNov 16, 2026
71Schonfeld Strategic Advisors LLC49,558-141,127 (-74.01%)0.02%$2 MNov 16, 2026
72Bank Of Montreal /can/47,473+4,903 (+11.52%)0.02%$1 MNov 9, 2026
73DAFNA Capital Management LLC46,5000 (0.00%)0.02%$1 MNov 16, 2026
74Exchange Traded Concepts, LLC45,508+14,735 (+47.88%)0.02%$1 MOct 28, 2026
75DCF Advisers, LLC45,000+12,900 (+40.19%)0.02%$1 MNov 4, 2026
76Osaic Holdings, Inc.44,938+152 (+0.34%)0.02%$1 MNov 12, 2026
77Mariner, LLC35,050-11,235 (-24.27%)0.02%$1 MNov 12, 2026
78TrueMark Investments, LLC33,083-517 (-1.54%)0.02%$1 MNov 5, 2026
79TD Asset Management Inc30,162-38,800 (-56.26%)0.01%$1 MNov 13, 2026
80Cormorant Asset Management, LP30,000-45,000 (-60.00%)0.01%$1 MNov 16, 2026
81Private Capital Advisors, Inc.29,7600 (0.00%)0.01%$1 MOct 6, 2026
82ADAR1 Capital Management, LLC27,500+10,000 (+57.14%)0.01%$1 MNov 16, 2026
83Nomura Asset Management Co LTD26,949-5,841 (-17.81%)0.01%$1 MNov 12, 2026
84EntryPoint Capital, LLC26,928+20,792 (+338.85%)0.01%$1 MNov 13, 2026
85Tower Research Capital LLC (TRC)23,726+22,829 (+2545.04%)0.01%$1 MNov 16, 2026
86Verition Fund Management LLC21,219-7,300 (-25.60%)0.01%$1 MNov 13, 2026
87Y-Intercept (Hong Kong) Ltd21,050-6,523 (-23.66%)0.01%$1 MOct 16, 2026
88Ameriprise Financial Inc20,368-210,146 (-91.16%)0.01%$1 MNov 16, 2026
89Handelsbanken Fonder AB19,4000 (0.00%)0.01%$1 MNov 9, 2026
90ANTIPODES PARTNERS Ltd19,088-32,174 (-62.76%)0.01%$1 MNov 5, 2026
91LPL Financial LLC18,667+4,334 (+30.24%)0.01%$1 MNov 6, 2026
92Voya Investment Management LLC18,385-26,025 (-58.60%)0.01%$1 MNov 10, 2026
93Flax Pond Capital, LLC17,688-55,312 (-75.77%)0.01%$1 MNov 18, 2026
94Teachers Retirement System Of The State Of Kentucky17,2970 (0.00%)0.01%$1 MNov 10, 2026
95SEI Investments Co16,548+2,864 (+20.93%)0.01%$1 MNov 10, 2026
96BNP Paribas Financial Markets14,968-2,813 (-15.82%)0.01%$0 MNov 12, 2026
97China Universal Asset Management Co., Ltd.14,957+2,548 (+20.53%)0.01%$0 MOct 28, 2026
98Stifel Financial Corp14,832-200 (-1.33%)0.01%$0 MNov 12, 2026
99DNB Asset Management As14,633+3,854 (+35.75%)0.01%$0 MNov 12, 2026
100Jump Financial, LLC14,323-28,335 (-66.42%)0.01%$0 MNov 13, 2026

All 171 institutional investors, with who bought and sold →

Mutual funds holding Structure Therapeutics Inc.#

129 funds in 2 countries hold shares worth $951 M (about 9.1% of the company). Since their previous reports 49 added shares and 51 sold, buying $15 M net. By country: USA 126 ($937 M), Sweden 3 ($14 M).
Mutual funds holding Structure Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Health Care FundWellington Management Company LLP3.28 M$157 M1.5%0.41%+13%Jul 31, 2026
🇺🇸 Heritage FundAmerican Century Investment Management, Inc.967,353$46 M0.45%0.87%no changeJul 31, 2026
🇺🇸 Global Emerging Markets FundPrincipal Global Investors, LLC625,751$30 M0.29%0.40%no changeJul 31, 2026
🇺🇸 Janus Henderson Global Life Sciences FundJanus Investment Fund549,353$29 M0.26%0.51%newJun 30, 2026
🇺🇸 Fidelity Advisor Growth Opportunities FundFidelity Management & Research Company LLC733,500$29 M0.34%0.08%no changeMay 31, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC527,900$25 M0.25%1.2%+9.7%Jul 31, 2026
🇺🇸 Janus Henderson Triton FundJanus Investment Fund467,112$25 M0.22%0.42%newJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.419,407$23 M0.20%0.19%−67%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors414,261$22 M0.19%0.24%+8.5%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC542,038$21 M0.25%0.40%−4.0%May 31, 2026
🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC540,000$21 M0.25%0.37%−13%May 31, 2026
🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC433,100$21 M0.20%0.28%+17%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC414,389$20 M0.19%0.23%no changeJul 31, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.405,606$19 M0.19%0.09%−30%Jul 31, 2026
🇺🇸 Aggressive Growth PortfolioPacific Heights Asset Management, LLC400,000$19 M0.19%3.8%no changeJul 31, 2026
🇺🇸 Permanent PortfolioPacific Heights Asset Management, LLC400,000$19 M0.19%0.27%no changeJul 31, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.301,239$16 M0.14%1.2%+81%Jun 30, 2026
🇺🇸 Fidelity ContrafundFidelity Management & Research Company LLC300,525$16 M0.14%<0.01%−62%Jun 30, 2026
🇺🇸 SmallCap FundPrincipal Global Investors, LLC287,100$14 M0.13%0.66%−4.1%Jul 31, 2026
🇺🇸 Janus Henderson Venture FundJanus Investment Fund252,725$14 M0.12%0.37%newJun 30, 2026
🇸🇪 SEB LäkemedelsfondSEB Funds AB245,043$13 M0.11%0.73%no changeJun 30, 2026
🇺🇸 Focused Dynamic Growth FundAmerican Century Growth Funds, Inc.263,026$13 M0.12%0.63%−18%Jul 31, 2026
🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC248,605$12 M0.12%0.25%−3.4%Jul 31, 2026
🇺🇸 Fidelity Advisor New Insights FundFidelity Management & Research Company LLC216,800$12 M0.10%0.04%−13%Jun 30, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.207,816$11 M0.10%0.08%−0.0%Jun 30, 2026
🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC228,000$11 M0.11%0.35%−19%Jul 31, 2026
🇺🇸 Fidelity FundFidelity Management & Research Company LLC197,200$11 M0.09%0.12%newJun 30, 2026
🇺🇸 Principal Capital Appreciation FundPrincipal Global Investors, LLC211,327$10 M0.10%0.26%−28%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC207,912$10 M0.10%0.22%no changeJul 31, 2026
🇺🇸 Fidelity Puritan FundFidelity Management & Research Company LLC244,500$10 M0.11%0.03%no changeMay 31, 2026
🇺🇸 abrdn World Healthcare Fundabrdn Inc.176,459$9 M0.08%1.7%+66%Jun 30, 2026
🇺🇸 The Hartford Growth Opportunities FundHartford Funds Management Company, LLC195,389$9 M0.09%0.14%−0.4%Jul 31, 2026
🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC230,777$9 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.162,217$9 M0.08%1.3%+36%Jun 30, 2026
🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc.178,989$9 M0.08%0.35%−3.4%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC147,713$8 M0.07%0.07%no changeJun 30, 2026
🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P.142,364$8 M0.07%0.24%−17%Jun 30, 2026
🇺🇸 AB Discovery Growth Fund, Inc.AllianceBernstein L.P.138,229$7 M0.06%0.26%−15%Jun 30, 2026
🇺🇸 Driehaus Small Cap Growth FundDriehaus Capital Management LLC137,401$7 M0.06%0.46%+11%Jun 30, 2026
🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC183,200$7 M0.09%<0.01%+4.5%May 31, 2026
🇺🇸 VIP Contrafund PortfolioFidelity Management & Research Company LLC126,600$7 M0.06%0.02%−21%Jun 30, 2026
🇺🇸 Mid Cap Growth FundJohn Hancock Investment Management LLC124,970$7 M0.06%0.50%−4.9%Jun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.136,424$7 M0.06%0.57%no changeJul 31, 2026
🇺🇸 Fidelity Series Opportunistic Insights FundFidelity Management & Research Company LLC117,800$6 M0.05%0.04%−13%Jun 30, 2026
🇺🇸 VIP Growth Opportunities PortfolioFidelity Management & Research Company LLC102,200$5 M0.05%0.10%−9.1%Jun 30, 2026
🇺🇸 Fidelity U.S. Equity Central FundFidelity Management & Research Company LLC100,000$5 M0.05%0.02%no changeJun 30, 2026
🇺🇸 Optimum Small-Mid Cap Growth FundDelaware Management Company95,119$5 M0.04%0.54%+186%Jun 30, 2026
🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC95,000$5 M0.04%0.44%−10%Jun 30, 2026
🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC98,200$5 M0.05%0.30%+44%Jul 31, 2026
🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC84,699$5 M0.04%0.76%−1.1%Jun 30, 2026
🇺🇸 Mid Cap Growth TrustJohn Hancock Variable Trust Advisers LLC82,492$4 M0.04%0.50%+11%Jun 30, 2026
🇺🇸 LVIP American Century Capital Appreciation FundLincoln Financial Investments Corporation80,497$4 M0.04%0.91%+26%Jun 30, 2026
🇺🇸 SA Wellington Capital Appreciation PortfolioSunAmerica Asset Management, LLC74,187$4 M0.03%0.15%+2.1%Jun 30, 2026
🇺🇸 The Hartford Healthcare FundHartford Funds Management Company, LLC79,359$4 M0.04%0.49%+10%Jul 31, 2026
🇺🇸 Fidelity Advisor Small Cap FundFidelity Management & Research Company LLC96,300$4 M0.04%0.16%no changeMay 31, 2026
🇺🇸 The Hartford Small Company FundHartford Funds Management Company, LLC72,884$4 M0.03%0.52%−2.3%Jul 31, 2026
🇺🇸 Fidelity Contrafund K6Fidelity Management & Research Company LLC63,742$3 M0.03%<0.01%−62%Jun 30, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company58,000$3 M0.03%0.41%no changeJun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC75,523$3 M0.04%<0.01%+38%May 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.73,020$3 M0.03%1.8%+35%May 31, 2026
🇺🇸 Brighthouse/Wellington Large Cap Research PortfolioBrighthouse Investment Advisers, LLC52,971$3 M0.02%0.11%−8.3%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC52,666$3 M0.02%0.13%+0.3%Jun 30, 2026
🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC57,300$3 M0.03%0.20%+57%Jul 31, 2026
🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC65,052$3 M0.03%<0.01%−1.3%May 31, 2026
🇺🇸 Hartford Small Company HLS FundHartford Funds Management Company, LLC47,674$3 M0.02%0.54%no changeJun 30, 2026
🇺🇸 Small Cap Growth Stock PortfolioMason Street Advisors, LLC47,654$3 M0.02%0.28%no changeJun 30, 2026
🇺🇸 American Century Focused Dynamic Growth ETFAmerican Century ETF Trust59,428$2 M0.03%0.57%+4.2%May 31, 2026
🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC47,095$2 M0.02%0.15%+17%Jul 31, 2026
🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC42,027$2 M0.02%0.83%no changeJun 30, 2026
🇺🇸 Fidelity Advisor Diversified Stock FundFidelity Destiny Portfolios41,600$2 M0.02%0.05%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC46,188$2 M0.02%0.09%−4.8%Jul 31, 2026
🇺🇸 Allspring Small Company Growth FundAllspring Funds Management, LLC42,632$2 M0.02%0.40%−1.2%Jul 31, 2026
🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC51,200$2 M0.02%<0.01%−13%May 31, 2026
🇺🇸 State Street SPDR S&P Emerging Markets Small Cap ETFSSGA Funds Management, Inc.35,893$2 M0.02%0.26%−6.8%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC47,468$2 M0.02%<0.01%+21%May 31, 2026
🇺🇸 Hartford Small Cap Growth HLS FundHartford Funds Management Company, LLC34,536$2 M0.02%0.28%no changeJun 30, 2026
🇺🇸 JNL Multi-Manager Small Cap Growth FundJackson National Asset Management, LLC33,631$2 M0.02%0.07%+13%Jun 30, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.33,261$2 M0.02%0.08%−4.3%Jun 30, 2026
🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P.33,101$2 M0.02%0.21%+27%Jun 30, 2026
🇺🇸 MassMutual Small Cap Growth Equity FundMML Investment Advisers, LLC32,929$2 M0.02%0.24%+3.7%Jun 30, 2026
🇺🇸 Adara Smaller Companies FundRBB Fund, Inc.41,403$2 M0.02%0.20%−17%May 31, 2026
🇺🇸 Small Cap Stock TrustJohn Hancock Variable Trust Advisers LLC30,081$2 M0.01%0.54%−1.8%Jun 30, 2026
🇺🇸 Column Small Cap Select FundTrust for Professional Managers36,453$1 M0.02%0.08%no changeMay 31, 2026
🇺🇸 SmallCap AccountPrincipal Global Investors, LLC26,300$1 M0.01%0.71%−1.1%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.25,918$1 M0.01%0.19%−67%Jun 30, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC23,797$1 M0.01%0.09%+563%Jun 30, 2026
🇺🇸 VIP Stock Selector PortfolioFidelity Management & Research Company LLC21,800$1 M0.01%0.02%no changeJun 30, 2026
🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB19,400$1 M<0.01%0.03%newJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC25,785$1 M0.01%0.14%−6.5%May 31, 2026
🇺🇸 Fidelity ZERO International Index FundFidelity Management & Research Company LLC20,385$1 M<0.01%<0.01%+14%Jul 31, 2026
🇺🇸 Brighthouse/Wellington Balanced PortfolioBrighthouse Investment Advisers, LLC17,717$1 M<0.01%0.07%+1.2%Jun 30, 2026
🇺🇸 Carillon Chartwell Small Cap FundCarillon Tower Advisers, Inc.17,480$1 M<0.01%0.37%no changeJun 30, 2026
🇺🇸 Principal Capital Appreciation AccountPrincipal Global Investors, LLC17,129$1 M<0.01%0.35%+34%Jun 30, 2026
🇺🇸 Fidelity Advisor Series Growth Opportunities FundFidelity Management & Research Company LLC22,800$1 M0.01%0.08%−21%May 31, 2026
🇺🇸 Inception PortfolioMorgan Stanley Investment Management Inc.16,316$1 M<0.01%0.31%no changeJun 30, 2026
🇺🇸 Empower Small Cap Growth FundEmpower Capital Management, LLC15,729$1 M<0.01%0.32%−8.2%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC20,734$1 M<0.01%<0.01%+19%May 31, 2026
🇺🇸 LVIP American Century Select Mid Cap Managed Volatility FundLincoln Financial Investments Corporation14,900$1 M<0.01%0.17%+25%Jun 30, 2026
🇺🇸 The Hartford Small Cap Growth FundHartford Funds Management Company, LLC15,161$1 M<0.01%0.26%−13%Jul 31, 2026
🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC13,328$1 M<0.01%0.07%−27%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Structure Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
14
since
Structure Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Crespo Blas CollCHIEF MEDICAL OFFICERConversion10b5-1 plan-12,024——258,228Form 4
filed Crespo Blas CollCHIEF MEDICAL OFFICERShares withheld for tax10b5-1 plan-10,626$11.67$124 K270,252Form 4
filed Xichen LinCHIEF SCIENTIFIC OFFICEROption exercise10b5-1 plan+17,817$0.340$6 K246,777Form 4
filed Xichen LinCHIEF SCIENTIFIC OFFICERConversion10b5-1 plan-17,817——228,960Form 4
filed Xichen LinCHIEF SCIENTIFIC OFFICEROption exercise10b5-1 plan+11,817$0.340$4 K240,777Form 4
filed Xichen LinCHIEF SCIENTIFIC OFFICERConversion10b5-1 plan-11,817——228,960Form 4
filed John Joseph BerriosChief Commercial OfficerGrant or award+140,766——140,766Form 4
filed Xichen LinCHIEF SCIENTIFIC OFFICEROption exercise10b5-1 plan+11,817$0.340$4 K240,777Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Structure Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
5.9 M
2.8% of shares · 6.5 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-1 split

Trading halts

  • 2025-12-08 15:17 UTC, code LUDP, resumed 15:22 UTC
  • 2025-12-08 15:03 UTC, code LUDP, resumed 15:08 UTC
  • 2025-12-08 14:40 UTC, code LUDP, resumed 14:45 UTC
  • 2025-12-08 14:33 UTC, code LUDP, resumed 14:38 UTC

Fails to deliver

  • : 42,724 shares at $22.01
  • : 3,299 shares at $22.31
  • : 912 shares at $23.91
  • : 30 shares at $25.67
  • : 2,000 shares at $28.98

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Structure Therapeutics Inc. scorecard#

Passes 1 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 20, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-4.8%Free cash flow is -4.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.80 vs -0.78Diluted EPS -0.80 in fiscal 2025 against -0.78 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$141 MNet income -$141 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-11.9%-11.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities24.8×Current ratio 24.82 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year12.5%Diluted shares up 12.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Structure Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Structure Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022
Income statement
Research and development2251097036
General and administrative62493316
Operating expenses17715810353
Operating income−177−158−103−53
Income before tax−141−122−89−51
Income tax0.50.30.20.0
Net income including minority interests−141−123−90−51
Net income attributable to shareholders−141−123−90−51
Earnings per share, basic-0.80-0.78-0.81-5.51
Earnings per share, diluted-0.80-0.78-0.81-5.51
Shares, weighted average (basic)1781581109.6
Shares, weighted average (diluted)1781581109.6
Balance sheet
Cash and cash equivalents80017013026
Short-term investments64771433865
Other current assets247.76.32.2
Current assets1,57089147493
Property, plant and equipment6.73.53.21.0
Right-of-use (leased) assets6.23.55.10.3
Total assets1,58490348298
Accounts payable148.04.76.0
Current liabilities63362513
Lease liabilities (non-current)3.62.24.0—
Total liabilities68382913
Retained earnings−470−329−207−117
Shareholders' equity1,516865453−115
Total liabilities and equity1,58490348298
Shares outstanding21317213911
Cash-flow statement
Share-based compensation29198.22.5
Cash from operating activities−222−117−79−46
Capital expenditure−3.6−1.3−2.2−0.2
Cash from investing activities90−359−268−62
Shares issued—515——
Cash from financing activities76351545229
Change in cash63040104−79
Report10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Structure Therapeutics Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 9 subsidiaries on file.

Present: offices, subsidiaries, branches or revenue (3 countries)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.
Structure Therapeutics Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office7 subsidiaries—
🇰🇾 Cayman Islands1 subsidiary—
🇭🇰 Hong Kong1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Structure Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$8.4 M
Raymond Stevens, Ph.D.
Other top executives, average
$3.0 M
the CEO earned 2.8× this
$100 invested is now
$268
peer group: $135
Structure Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Raymond Stevens, Ph.D.$8.4 M$36.2 M$3.0 M$268 (peers $135)
2024Chief executive$5.7 M$1.7 M$3.6 M$104 (peers $101)
2023Chief executive$7.4 M$22.1 M$2.2 M$157 (peers $102)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Structure Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 2 · Shareholder vote 3 · Results announced 11

Structure Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Material agreementResults announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

H-1B hiring at Structure Therapeutics Inc.#

1 labor condition applications certified in fiscal 2021 for 1 positions, at a median wage of $300 K a year.

Certified, FY2021
1
#2,062 among companies on value.today
Worker positions
1
Median wage offered
$300 K
a year, full-time
Applications filed
1
Structure Therapeutics Inc.: most frequent H-1B job titles in fiscal 2021
Job titlePositionsMedian wage offered
Senior Vice President, Cardiopulmonary Clinical DevelopmentClinical Research Coordinators1$300 K

Where: South San Francisco, CA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as ShouTi Inc.

Discuss Structure Therapeutics Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 9 November 2026automatic update · Nov 9, 2026

    Structure Therapeutics Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $145 million.

  • Mutual funds: 129 funds hold $951 millionautomatic update · Jul 31, 2026

    129 mutual funds in 2 countries hold shares of Structure Therapeutics Inc. worth $951 million, about 9.1% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 49 funds added shares and 51 sold; on balance they bought $15 million. Share splits are not counted as trading.

How Structure Therapeutics Inc. compares in Biotechnology

  • Market cap$4.7 B · higher than 89% of 726
  • Price / book3.1× · lower than 47% of 534
  • FCF yield-4.8% · higher than 73% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Structure Therapeutics Inc.🇺🇸$4.7 B———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 20, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Structure Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Structure Therapeutics Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Structure Therapeutics Inc.? Suggest a correction